This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To assess the relevance of quantitative EEG (qEEG) measures as outcomes of disease severity and progression in Parkinson disease (PD).
Methods Main databases were systematically searched (January 2018) for studies of sufficient methodologic quality that examined correlations between clinical symptoms of idiopathic PD and cortical (surface) qEEG metrics.
Results Thirty-six out of 605 identified studied were included. Results were classified into 4 domains: cognition (23 studies), motor function (13 studies), responsiveness to interventions (7 studies), and other (10 studies). In cross-sectional studies, EEG slowing correlated with global cognitive impairment and with diffuse deterioration in other domains. In longitudinal studies, decreased dominant frequency and increased θ power, reflecting EEG slowing, were biomarkers of cognitive deterioration at an individual level. Results on motor dysfunction and treatment yielded contrasting findings. Studies on functional connectivity at an individual level and longitudinal studies on other domains or on connectivity measures were lacking.
Conclusion qEEG measures reflecting EEG slowing, particularly decreased dominant frequency and increased θ power, correlate with cognitive impairment and predict future cognitive deterioration. qEEG could provide reliable and widely available biomarkers for nonmotor disease severity and progression in PD, potentially promoting early diagnosis of nonmotor symptoms and an objective monitoring of progression. More studies are needed to clarify the role of functional connectivity and network analyses.
Glossary
- BRF=
- background rhythm frequency;
- DBS=
- deep brain stimulation;
- EWCI=
- edge-wise connectivity index;
- FFT=
- fast Fourier transformation;
- H&Y=
- Hoehn & Yahr;
- JBI=
- Joanna Briggs Institute;
- LFP=
- local field potentials;
- MCI=
- mild cognitive impairment;
- MDS-UPDRS III=
- Movement Disorders Society–Unified Parkinson's Disease Rating Scale III;
- MEG=
- magnetoencephalography;
- MST=
- minimum spanning trees;
- NCOG=
- cognitively normal;
- PD=
- Parkinson disease;
- PDD=
- Parkinson disease dementia;
- PLI=
- phase-lag index;
- PLV=
- phase-locking value;
- PRISMA=
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses;
- qEEG=
- quantitative EEG;
- RBD=
- REM sleep behavior disorder;
- WN=
- weighted network
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- © 2018 American Academy of Neurology
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.